Residues of genotoxic alkyl mesylates in mesylate salt drug substances: Real or imaginary problems?

Regulatory Toxicology and Pharmacology

Volumn 45, Issue 1, 2006, Pages 79-90

  Snodin, David J ^a  

^a PAREXEL INTERNATIONAL   (United States)

Author keywords

Alkylating agents; Carcinogenicity; EMS; Genotoxicity; MMS; SN1; SN2; Swain Scott constants

Indexed keywords

ALCOHOL; ALKYL GROUP; ALKYLATING AGENT; AMINE; BASE; BROMIDE; CARCINOGEN; CHLORIDE; ESTER; HALIDE; MESYLIC ACID; MESYLIC ACID DERIVATIVE; SODIUM CHLORIDE; SOLVENT; SULFONIC ACID DERIVATIVE;

ADDITION REACTION; ARTICLE; CARCINOGENICITY; CHEMICAL REACTION; CRYSTALLIZATION; GENOTOXICITY; HUMAN; HYDROLYSIS; NONHUMAN; PH; PRIORITY JOURNAL; SYNTHESIS;

ALKYLATING AGENTS; ANIMALS; CARCINOGENS; CHEMISTRY, PHARMACEUTICAL; HUMANS; MESYLATES; MOLECULAR STRUCTURE; MUTAGENS; PHARMACEUTICAL PREPARATIONS; SALTS;

EID: 33646089419     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2006.02.003     Document Type: Article

References (80)

1. Aitio A. Zero exposure-a goal for environmental and occupational health?. Toxicol. Lett. 134 (2002) 3-8
2. Ames B., and Gold L. Paracelsus to parascience; the environmental cancer distraction. Mutat. Res. 447 (2000) 3-13
3. Barbin A., and Bartsch H. Nucleophilic selectivity as a determinant of carcinogenic potency (TD50) in rodents: a comparison of mono- and bi-functional alkylating agents and vinyl chloride metabolites. Mutat. Res. 215 (1989) 95-106
4. Bartsch H., Malaveille C., Tomatis L., Brun G., Dodet B., and Terracini B. Quantitative comparisons between carcinogenicity, mutagenicity and electrophilicity of direct-acting N-nitroso compounds and other alkylating agents. IARC Sci. Publ. 41 (1982) 525-532
5. Bartsch H., Terracini B., Malaveille C., Tomatis L., Wahrendorf J., Brun G., and Dodet B. Quantitative comparison of carcinogenicity, mutagenicity and electrophilicity of 10 direct-acting alkylating agents and of the initial O6:7-alkylguanine ratio in DNA with carcinogenic potency in rodents. Mutat. Res. 110 (1983) 181-219
6. N2 reactions with high carbocation character. JCS Perkin II (1978) 557-562
7. Beranek D.T. Distribution of methyl and ethyl adducts following alkylation with monofunctional alkylating agents. Mutat. Res. 231 (1990) 11-30
8. Boffa L.C., Bolognesi C., and Mariani M.R. Specific targets of alkylating agents in nuclear proteins of cultured hepatocytes. Mutat. Res. 190 (1987) 119-123
9. Carey F.A. Organic Chemistry (2003), McGraw Hill
10. Connelly J.C., Hasegawa R., McArdle J.V., and Tucker M.L. ICH guideline: residual solvents. Pharmeuropa 9 Suppl. 1 (1997)
11. Couch D.B., Forbes N.L., and Hsie A.W. Comparative mutagenicity of alkylsulfate and alkanesulfonate derivatives in Chinese hamster ovary cells. Mutat. Res. 57 (1978) 217-224
12. Council of Europe. 2000. Enquiry: alkyl mesilate (methanesulphonate) impurities in mesilate salts. Pharmeuropa. 12, 27.
13. Drablos F., Feyzi E., Aas P.A., Vaagbo C.B., Kavli B., Bratlie M.S., Pena-Diaz J., Otterlei M., Slupphaug G., and Krokan H.E. Alkylation damage in DNA and RNA-repair mechanisms and medical significance. DNA Repair (Amst). 3 (2004) 1389-1407
14. Eder E., and Kutt W. The dependence of the mutagenicity of methanesulphonic acid esters in S. typhimurium TA100 on the alkylation mechanism. Chem. Biol. Interact. 69 (1989) 45-59
15. Eder E., Deininger C., and Wiedenmann M. Methyl methanesulphonate (MMS) is clearly mutagenic in S. typhimurium strain TA 1535; a comparison with strain TA 100. Mutat. Res. 226 (1989) 145-149
16. Eder E., Deininger C., and Kutt W. Genotoxicity of monofunctional methanesulphonates in the SOS chromotest as a function of alkylation mechanisms. A comparison with the mutagenicity in S. typhimurium TA100. Mutat. Res. 211 (1989) 51-64
17. Eder E., Kutt W., and Deininger C. On the role of alkylating mechanisms, O-alkylation and DNA-repair in genotoxicity and mutagenicity of alkylating methanesulfonates of widely varying structures in bacterial systems. Chem. Biol. Interact. 137 (2001) 89-99
18. Ehrenberg L., Granath F., and Tornqvist M. Macromolecule adducts as biomarkers of exposure to environmental mutagens in human populations. Environ. Health Perspect. 104 Suppl. 3 (1996) 423-428
19. EMEA. 2004. Guideline on the limits of genotoxic impurities. .
20. Engel G.L., Farid N.A., Faul M.M., Richardson L.A., and Winneroski L.L. Salt form selection and characterization of LY333531 mesylate monohydrate. Int. J. Pharm. 198 (2000) 239-247
21. EPA, IRIS (Environmental Protection Agency, Integrated Risk Information System). .
22. Ferguson L.R. Natural and man-made mutagens and carcinogens in the human diet. Mutat. Res. 443 (1999) 1-10
23. Ferguson L.R., Turner P.M., Pogai H., and Denny W.A. Modulation of mutagenic properties in a series of DNA-directed alkylating agents by variation of chain length and alkylator reactivity. Mutat. Res. 265 (1992) 181-193
24. Fox M., and Brennand J. Evidence for the involvement of lesions other than O6-alkylguanine in mammalian cell mutagenesis. Carcinogenesis 1 (1980) 795-799
25. Glowienke S., Frieauff W., Allmendinger T., Martus H.J., Suter W., and Mueller L. Structure-activity considerations and in vitro approaches to assess the genotoxicity of 19 methane-, benzene- and toluenesulfonic acid esters. Mutat. Res. 581 (2005) 23-34
26. Haglund J., Ehrenberg L., and Tornqvist M. Studies of transalkylation of phosphotriesters in DNA: reaction conditions and requirements on nucleophiles for determination of DNA adducts. Chem. Biol. Interact. 108 (1997) 119-133
27. Hemminki K., Falck K., and Vainio H. Comparison of alkylation rates and mutagenicity of directly acting industrial and laboratory chemicals: epoxides, glycidyl ethers, methylating and ethylating agents, halogenated hydrocarbons, hydrazine derivatives, aldehydes, thiuram and dithiocarbamate derivatives. Arch. Toxicol. 46 (1980) 277-285
28. Hengstler J.G., Bogdanffy M.S., Bolt H.M., and Oesch F. Challenging dogma: thresholds for genotoxic carcinogens? The case of vinyl acetate. Annu. Rev. Pharmacol. Toxicol. 43 (2003) 485-520
29. HSDB (Hazardous Substances Data Bank). .
30. IARC (1). .
31. IARC (2). .
32. ICH, Q3C: Impurities: residual solvents. .
33. Kaina B. Mechanisms and consequences of methylating agent-induced SCEs and chromosomal aberrations: a long road traveled and still a far way to go. Cytogenet. Genome Res. 104 (2004) 77-86
34. Kirkland D.J., and Müller L. Interpretation of genotoxicity test results: the importance of thresholds. Mutat. Res. 464 (2000) 137-147
35. Kirkland D.J., and Snodin D.J.. Setting limits for genotoxic impurities in drug substances; threshold-based and pragmatic approaches. Int. J. Pharm. Med. 18 (2004) 197-207
36. Kleihues P., Doerjer G., Swenberg J.A., Hauenstein E., Bucheler J., and Cooper H.K. DNA repair as regulatory factor in the organotropy of alkylating carcinogens. Arch. Toxicol. Suppl. 1979 (1979) 253-261
37. Kornfeld, E.C., Bach, N.J., 1980. 6-Ethyl(or allyl)-8-methoxymethyl or methylmercaptomethylergolines and related compounds. US Patent 4, 202, 979.
38. Kyrtopoulos S.A. Variability in DNA repair and individual susceptibility to genotoxins. Clin. Chem. 41 (1995) 1848-1853
39. Kyrtopoulos S.A. O6-Alkylguanine-DNA alkyltransferase: influence on susceptibility to the genetic effects of alkylating agents. Toxicol. Lett. 102-103 (1996) 53-57
40. Lee G.S., Blonsky K.S., Van On D.L., Savage E.A., Morgan A.R., and von Borstel R.C. Base alterations in yeast induced by alkylating agents with differing Swain-Scott substrate constants. J. Mol. Biol. 223 (1992) 617-626
41. Lee C.R., Guivarch F., Nguyen Van Dau C., Tessier D., and Krstulovic A.M. Determination of polar alkylating agents as thiocyanate/isothiocyanate derivatives by reaction headspace gas chromatography. Analyst 128 (2003) 857-863
42. Li W. Trace analysis of residual methyl methanesulfonate, ethyl methanesulfonate and isopropyl methanesulfonate in pharmaceuticals by capillary gas chromatography with flame ionization detection. J. Chromatogr. A 1046 (2004) 297-301
43. Li S., Wong S., Sethia S., Almoazen H., Joshi Y.M., and Serajuddin A.T. Investigation of solubility and dissolution of a free base and two different salt forms as a function of pH. Pharm. Res. 22 (2005) 628-635
44. Lohman P.H. Qualitative and quantitative procedures for health risk assessment. Mutat. Res. 428 (1999) 237-254
45. Margison G.P., Santibanez Koref M.F., and Povey A.C. Mechanisms of carcinogenicity/chemotherapy by O6-methylguanine. Mutagenesis 17 (2002) 483-487
46. Miller, S.A., Ju, J., Cucolo, M., Dai, J.Y., Jia, J., Narra, K., Smith, A.M., Aubry, A.-F., 2004. A new capillary GC/MS method for determining ethyl methanesulfonate (EMS) and its stability in a drug product formulation, Poster at 52nd ASMS Conference.
47. Morisseau M., and Hammock B.D. Epoxide hydrolases: mechanisms, inhibitor designs, and biological roles. Annu. Rev. Pharmacol. Toxicol. 45 (2005) 311-333
48. Morita T., Asano N., Awogi T., Sasaki Y.F., Sato S., Shimada H., Sutou S., Suzuki T., Wakata A., Sofuni T., and Hayashi M. Evaluation of the rodent micronucleus assay in the screening of IARC carcinogens (groups 1, 2A and 2B) the summary report of the 6th collaborative study by CSGMT/JEMS MMS. Collaborative Study of the Micronucleus Group Test. Mammalian Mutagenicity Study Group. Mutat. Res. 389 (1997) 3-122
49. Moustacchi E. DNA damage and repair: consequences on dose-responses. Mutat. Res. 464 (2000) 35-40
50. Müller L., and Kasper P. Human biological relevance and the use of threshold arguments in regulatory genotoxicity assessment: experience with pharmaceuticals. Mutat. Res. 464 (2000) 19-34
51. Müller L., Mauthe R.J., Riley C.M., Andino M.M., Antonis D.D., Beels C., Degeorge J., De Knaep A.G., Ellison D., Fagerland J.A., Frank R., Fritschel B., Galloway S., Harpur E., Humfrey C.D., Jacks A.S., Jagota N., Mackinnon J., Mohan G., Ness D.K., O'Donovan M.R., Smith M.D., Vudathala G., and Yotti L. A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity. Regul. Toxicol. Pharmacol. (2006) [Epub ahead of print]
52. Newbold R.F., Warren W., Medcalf A.S., and Amos J. Mutagenicity of carcinogenic methylating agents is associated with a specific DNA modification. Nature 283 5747 (1980) 596-599
53. Oh H.K., Teo A.K., Ali R.B., Lim A., Ayi T.C., Yarosh D.B., and Li B.F. Conformational change in human DNA repair enzyme O6-methylguanine-DNA methyltransferase upon alkylation of its active site by SN1 (indirect-acting) and SN2 (direct-acting) alkylating agents: breaking a "salt-link". Biochemistry 35 (1996) 12259-12266
54. Pearson R.G., and Songstad J. Application of the principle of hard and soft acids and bases to organic chemistry. J. Am. Chem. Soc. 89 (1967) 1827-1836
55. Pegg A.E. Properties of the O6-alkylguanine-DNA repair system of mammalian cells. IARC Sci. Publ. 57 (1984) 575-580
56. Prestera T., Zhang Y., Spencer S.R., Wilczak C.A., and Talalay P. The electrophile counterattack response: protection against neoplasia and toxicity. Adv. Enzyme Regul. 33 (1993) 281-296
57. Rajewsky M.F., Engelbergs J., Thomale J., and Schweer T. DNA repair: counteragent in mutagenesis and carcinogenesis - accomplice in cancer therapy resistance. Mutat. Res. 462 (2000) 101-105
58. Ramjit H.G., Singh M.M., and Coddington A.B. Gas chromatographic/mass spectrometric analysis of methyl methanesulphonate and ethyl methanesulphonate of DPI 201-106, a positive inotropic agent for the treatment of heart failure. J. Mass Spectrom. 31 (1996) 867-872
59. Sega G.A. A review of the genetic effects of ethyl methanesulfonate. Mutat. Res. 134 (1984) 113-142
60. Sega G.A., Wolfem K.W., and Owensm J.G. A comparison of the molecular action of an SN1-type methylating agent, methyl nitrosourea and an SN2-type methylating agent, methyl methanesulfonate, in the germ cells of male mice. Chem. Biol. Interact. 33 (1981) 253-269
61. Segal A., Seidman I., and Melchionne S. Induction of thymic lymphomas and squamous cell carcinomas following topic application of isopropyl methanesulfonate to female Hsd:(ICR)BR mice. Cancer Res. 47 (1987) 3402-3405
62. Singer B. Alkylation of the O6 of guanine is only one of many chemical events that may initiate carcinogenesis. Cancer Invest. 2 (1984) 233-238
63. Sledziewska-Gojska E. Inactivation of O6-methylguanine-DNA methyltransferase in vivo by SN2 alkylating agents. Mutat. Res. 336 (1995) 61-67
64. Sledziewska-Gojska E., and Torzewska D. Different repair of O6-methylguanine occurring in DNA modified by MMS in vivo or in vitro. Mutat. Res. 383 (1997) 31-37
65. Smith G.J., and Grisham J.W. Cytotoxicity of monofunctional alkylating agents. Methyl methanesulfonate and methyl-N'-nitro-N-nitrosoguanidine have different mechanisms of toxicity for 10T1/2 cells. Mutat. Res. 111 (1983) 405-417
66. Swain C.G., and Scott C.B. Quantitative correlation of reaction rates. Comparison of hydroxide ion with other nucleophilic reagents towards alkyl halides, esters, epoxides and acyl halides. J. Am. Chem. Soc. 75 (1953) 141-147
67. Swenson D.H. Significance of electrophilic reactivity and especially DNA alkylation in carcinogenesis and mutagenesis. Dev. Toxicol. Environ. Sci. 11 (1983) 247-254
68. Swenson D.H., and Lawley P.D. Alkylation of deoxyribonucleic acid by carcinogens dimethyl sulphate, ethyl methanesulphonate, N-ethyl-N-nitrosourea and N-methyl-N-nitrosourea. Relative reactivity of the phosphodiester site thymidylyl(3'-5')thymidine. Biochem. J. 171 (1978) 575-587
69. Tornqvist M. Ethylene oxide as a biologically reactive intermediate of endogenous origin. Adv. Exp. Med. Biol. 387 (1996) 275-283
70. Ukawa S., and Mochizuki M. Biological and chemical properties of alkanediazotates as active species of N-nitroso compounds. IARC Sci. Publ. 105 (1991) 404-406
71. Varsal Inc, .
72. Vogel E.W., and Nivard M.J. International Commission for Protection Against Environmental Mutagens and Carcinogens. The subtlety of alkylating agents in reactions with biological macromolecules. Mutat. Res. 305 (1994) 13-32
73. Vogel E.W., Barbin A., Nivard M.J., and Bartsch H. Nucleophilic selectivity of alkylating agents and their hypermutability in Drosophila as predictors of carcinogenic potency in rodents. Carcinogenesis 11 (1990) 2211-2217
74. Vogel E.W., Nivard M.J., Ballering L.A., Bartsch H., Barbin A., Nair J., Comendador M.A., Sierra L.M., Aguirrezabalaga I., Tosal L., Ehrenberg L., Fuchs R.P., Janel-Bintz R., Maenhaut-Michel G., Montesano R., Hall J., Kang H., Miele M., Thomale J., Bender K., Engelbergs J., and Rajewsky M.F. DNA damage and repair in mutagenesis and carcinogenesis: implications of structure-activity relationships for cross-species extrapolation. Mutat. Res. 353 (1996) 177-218
75. Vogel E.W., Barbin A., Nivard M.J., Stack H.F., Waters M.D., and Lohman P.H. Heritable and cancer risks of exposures to anticancer drugs: inter-species comparisons of covalent deoxyribonucleic acid-binding agents. Mutat. Res. 400 (1998) 509-540
76. Wahnschaffe U., Bitch A., Kielhorn J., and Mangelsdorf I. Mutagenicity testing with transgenic mice. Part I: comparison with the mouse bone marrow micronucleus test. J. Carcinog. 4 (2005) 3
77. Wahnschaffe U., Bitch A., Kielhorn J., and Mangelsdorf I. Mutagenicity testing with transgenic mice. Part II: comparison with the mouse spot test. J. Carcinog. 4 (2005) 4
78. Walles S.A. Determination of reaction rate constants for alkylation of 4-(p-nitrobenzyl) pyridine by different alkylating agents. Toxicol. Lett. 5 (1980) 161-167
79. Wohl, R.A., 1980. Process for preparing substituted bis(aminoureas). US Patent 4, 209, 624.
80. Yamada M., Matsui K., Sofuni T., and Nohmi T. New tester strains of Salmonella typhimurium lacking O6-methylguanine DNA methyltransferases and highly sensitive to mutagenic alkylating agents. Mutat. Res. 381 (1997) 15-24